Annovis Bio Inc ANVS 深 滬
交易中 05-18 11:14:39 美东时间
2.085
+0.025
+1.21%
華盛通- 最 高2.139
- 今 開2.05
- 成交量 15.20万股
- 最 低 2.03
- 昨 收 2.06
- 總市值 7223.87万
- 52周最高 5.50
- 市盈率 靜 --
- 換手率 0.44%
- 52周最低 1.5407
- 委 比 -33.33%
- 總股本 3464.69万
- 歷史最高 132.00
- 量 比 0.89
- 振 幅 5.29%
- 歷史最低 1.11
- 每 手 1
- 風險率 0.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Annovis Bio Q1 EPS $(0.63) Misses $(0.40) Estimate
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.40) by 61.54 percent. This is a 96.88 percent decrease over losses of $(0.32) per share from the
05-15 19:38
Annovis Bio Q1 FY26 net loss widens to $17.61 million
Annovis Bio Q1 FY26 net loss widens to $17.61 million Annovis Bio posted a net loss of USD 17.61 million, or USD 0.63 per share, for first-quarter 2026, widening from a net loss of USD 5.54 million, or USD 0.32 per share, a year earlier. Research and development expense more than doubled to USD 16.
05-15 19:32
Annovis Bio Announces New Publication Titled Buntanetap Treatment In Mild To Moderate Alzheimer's Disease: Phase 2/3 Study In Peer-Reviewed Journal Nature NPJ Dementia
Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tolerated, including in
04-28 20:10
Annovis Bio shares are trading lower after the company announced pricing of its $10 million offering of common stock and warrants.
Annovis Bio shares are trading lower after the company announced pricing of its...
04-09 22:31
Annovis Bio Issued New U.S. Patent For Prevention And Treatment Of Neurological Injuries From Brain Infections
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's
04-02 19:31
Annovis Bio wins U.S. patent for buntanetap to treat brain infection-related injuries
Annovis Bio wins U.S. patent for buntanetap to treat brain infection-related injuries Annovis Bio secured U.S. Patent No. 12,582,632 B2 covering use of buntanetap to prevent or treat neurological injuries linked to brain infections. Patent claims include preventive use in at-risk healthy individuals
04-02 19:30
Annovis Publishes Historical Review of Buntanetap in The Scientist
Annovis Bio, Inc. (NYSE: ANVS) announced the publication of an article in *The Scientist* detailing the history and development of buntanetap, its lead drug candidate for neurodegenerative diseases like Alzheimer's and Parkinson's. The article traces buntanetap's journey from its 19th-century origins through its current Phase 3 clinical trials, with 70% of early Alzheimer's patients enrolled. Buntanetap is also being tested in an open-label Parki...
03-31 12:00
Annovis Bio partners with NeuroRPM for AI wearable monitoring in Parkinson’s trial
Annovis Bio partners with NeuroRPM for AI wearable monitoring in Parkinson’s trial Annovis partnered with NeuroRPM to use NeuroRPM’s FDA-cleared wearable platform for digital biomarker monitoring in Annovis’s ANVS-25002 open-label Parkinson’s disease clinical trial. The NeuroRPM platform uses Apple
03-19 19:31
Annovis Bio partners with NeuroRPM to deploy FDA-cleared AI digital biomarkers in Parkinson’s study
Annovis Bio partners with NeuroRPM to deploy FDA-cleared AI digital biomarkers in Parkinson’s study Annovis partnered with NeuroRPM to deploy an FDA-cleared AI platform for movement-data collection in an ongoing Parkinson’s disease study. The platform is intended to monitor bradykinesia, tremor, and
03-19 19:31
